Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.35 |
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.33 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.32 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | S100B | P04271 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6472903 | 1.00 | CYP3A4 (0.50) | CYP3A4TSHRPIK3CAALDH1A1S100B | |
| SCHEMBL6472907 | 0.98 | CYP3A4 (0.52) | CYP3A4TSHRPIK3CAALDH1A1S100B | |
| Hydrochloric Acid SCHEMBL6480110 | 0.81 | ALDH1A1 (0.41) | CYP3A4TSHRALDH1A1S100BTDP1 | |
| Hydrochloric Acid SCHEMBL6639005 | 0.81 | ALDH1A1 (0.41) | CYP3A4TSHRALDH1A1S100BTDP1 | |
| SCHEMBL15928725 | 0.80 | CYP3A4 (0.50) | CYP3A4TSHRPIK3CAALDH1A1S100B | |
| Hydrochloric Acid SCHEMBL10630985 | 0.79 | ALDH1A1 (0.38) | CYP3A4TSHRALDH1A1S100BMAPK1 | |
| SCHEMBL10700706 | 0.79 | ALDH1A1 (0.44) | CYP3A4TSHRPIK3CAALDH1A1S100B | |
| SCHEMBL50190 | 0.79 | ALDH1A1 (0.43) | CYP3A4TSHRALDH1A1S100BTDP1 | |
| Sulfuric Acid SCHEMBL8624039 | 0.78 | MEN1 (0.38) | CYP3A4TSHRPIK3CAALDH1A1S100B | |
| SCHEMBL11528402 | 0.78 | CYP3A4 (0.36) | CYP3A4TSHRPIK3CAALDH1A1S100B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004155-B1 | INHIBITORS OF PROTEIN AGGREGATION | WISTA LAB LTD (SG) | 2018-02-21 | — | — | EP | disclosed |
| EP-2853293-B1 | Thioninium compounds and their use | WISTA LAB LTD (SG) | 2017-11-22 | — | — | EP | disclosed |
| EP-2853293-A1 | Thioninium compounds and their use | WisTa Laboratories Ltd. (SG) | 2015-04-01 | — | — | EP | disclosed |
| EP-2001556-B1 | THIONINIUM COMPOUNDS AND THEIR USE | WISTA LAB LTD (SG) | 2014-10-01 | — | — | EP | disclosed |
| US-8263589-B2 | Inhibitors of protein aggregation | WISTA LABORATORIES LTD. (SG) | 2012-09-11 | — | — | US | disclosed |
| US-7737138-B2 | Methods of treatment of a tauopathy condition comprising the use of thioninium compounds | WISTA LABORATORIES LTD. (SG) | 2010-06-15 | — | — | US | disclosed |
| US-20090209526-A1 | INHIBITORS OF PROTEIN AGGREGATION | WISTA LABORATORIES LTD | 2009-08-20 | — | — | US | disclosed |
| US-20060287523-A1 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | WISTA LABORATORIES LTD. (SG) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209526-A1 | INHIBITORS OF PROTEIN AGGREGATION | SNCA, PARK7, HTT | PIK3CA 4816/4885GAA 232/4885NR3C1 4802/4885 |
| US-20060287523-A1 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) | MGMT, MAPT, TST | PIK3CA 4505/4885GAA 1580/4885NR3C1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.